The company continued to add new customers in the quarter, with 90 percent of its U.S. Waterlase sales from new buyers.
Biolase is anticipating its fourth-quarter revenue to be more than $13 million and its total 2022 revenue to rise at least 20 percent compared to 2021, the release said.